Mocetinostat is a histone deacetylase (HDAC) inhibitor undergoing clinical trials for treatment of many cancers including follicular lymphoma, Hodgkin’s lymphoma and acute myelogenous leukemia. Here, HDAC9 is linked to Hodgkins lymphoma.